Unraveling cocaine metabolism in patients with cocaine use disorder for the purpose of potentially improving bioanalytical tests for cocaine use - Unraveling cocaine metabolism in patients with CUD

Start Date12 Nov 2024

Sponsor / Collaborator-

NCT06443255

/ CompletedPhase 3IIT

Comparison of Cocaine, Lidocaine/xylometazoline and Saline for Intranasal Analgesia - a Blinded Triple Crossover Study

When performed by trained personnel nasotracheal intubation is a safe and effective technique for attaining a secure airway in preparation for surgery of the head and neck. The procedure can be deemed necessary due to the nature of the surgical procedure or considerations in regard to the patient's comorbidities. For a certain group of patients with expected difficult airways, the procedure is done whilst they are awake and aided by fiberoptics.
For these awake patients, extra precautions must be taken to ensure the procedure is conducted with minimal pain and discomfort. The pain and discomfort arises from the mechanical manipulation of the nasal mucosa and can be alleviated in part by means of topical analgesia as well as through decongestion, providing more space within the nasal cavity. For these purposes, several drugs in varying combinations and dosages are used, but no single drug choice is universally recommended.
Cocaine is one of these appropriate drugs. It is a magistral formula used especially due to its unique combination of both vasoconstrictive and analgesic properties. Concerns have though been raised regarding cocaine's potential toxicity and alternative medications are continuously sought after.
A combination of lidocaine and xylometazoline can also be used for preparation of the nose prior to awake nasal fiberoptic intubation. Lidocaine contributes with its analgesic effect whilst xylometazoline functions as the vasoconstrictor.
The investigators wish to compare the analgesic effects of cocaine and lidocaine/phenylephrine to each other and saline when subjectively scored on a visual analogue scale of 0-100 mm immediately after simulated awake nasal intubation on healthy volunteers.

Start Date01 Jul 2024

Sponsor / Collaborator

Rigshospitalet

NCT05809453

/ CompletedPhase 1/2IIT

Intranasal Cocaine and Temperature Regulation During Exercise

Assess the effects of intranasal cocaine on temperature regulation and whole-body sweat rate during exercise in warm environmental conditions.

Start Date01 Sep 2023

Sponsor / Collaborator

The University of Texas Southwestern Medical Center

100 Clinical Results associated with Cocaine Hydrochloride

100 Translational Medicine associated with Cocaine Hydrochloride

100 Patents (Medical) associated with Cocaine Hydrochloride

49,618

Literatures (Medical) associated with Cocaine Hydrochloride

01 Nov 2025·NEUROPHARMACOLOGY

Article

Author: Montgomery, Joreylis Michelle F ; Bi, Ziqian ; Fang, Shiaofen ; Guo, Changyong ; Ma, Yao-Ying ; Fu, Haoying ; Chen, Yingying ; Rayanki, Chandrashekar ; Korada, Amith ; Lange, Michal A

Addiction is a chronic mental disorder caused by disruptions in brain function. While most research has focused on the medial prefrontal cortex, our recent findings highlight the secondary motor cortex (M2) as a key region modulating cocaine-seeking behaviors during relapse. Mechanisms underlying the role of M2 in addiction remain unclear. We hypothesize that initial drug-taking behaviors directly reshape M2 neuronal activity. This study investigated the effects of five 1-hr daily intravenous self-administration (IVSA) sessions on M2 neuronal activity in male C57BL/6J mice using in vivo Ca²⁺ imaging via miniScopes. Temporal and spatial patterns of Ca²⁺ transients were analyzed across three IVSA factors: IV substance (i.e., saline vs. cocaine), IVSA days, and within-session stages. Machine learning models, including Recurrent Neural Networks for temporal patterns, and Neural Networks, Support Vector Machines, and Extreme Gradient Boosting for spatial patterns, were employed. RESULTS: Cocaine-treated mice displayed consistent drug-taking behaviors within sessions and increased intake on Day 5 compared to Day 1, unlike saline-treated mice, which showed reduced operant behaviors within each daily session. IV substance was the most sensitive factor influencing both temporal and spatial patterns of M2 Ca²⁺ transients, characterized by frequency and frequency-amplitude interactions, but not amplitude alone. A 15-s bin size optimized differentiation between saline and cocaine groups. CONCLUSION: Both temporal and spatial alterations in M2 neuronal activity were detected during early cocaine exposure, revealing early changes that may contribute to later drug relapse. These findings underscore the importance of advanced imaging and machine learning techniques in advancing addiction research.

01 Oct 2025·Medicina de Familia-SEMERGEN

Tentativa de suicidio: evolución de las visitas en Urgencias de un hospital comarcal en Barcelona, estudio transversal de 2019 a 2023

Article

Author: Guil Sànchez, J

OBJECTIVE:

To study the characteristics of patients who consulted in the emergency department for suicide attempts between 2019-2023 and the characteristics of the episodes.

MATERIAL AND METHODS:

Descriptive study from 1 January 2019 to 31 December 2023. We included demographic variables (sex, age), clinical variables (psychiatric history, psychotropic medication, substance abuse, follow-up in Mental Health, existence of previous self-harm attempt) and characteristics of the episode (mechanism, motive, destination).

RESULTS:

810 patients consulted, 64.6% women, mean age 39.6±18.1. They had a psychiatric history 688 (84.9%): men 228 (79.4%), women 460 (87.9%). Follow-up in Mental Health 384(47,4%): men 115 (40,1%), women 269 (51,4%). They had a previous suicide attempt 271 (33.5%): men 78 (27.2%), women 193 (36.9%). They used intoxicants 226(32.8%): men 131 (45.6%), women 135 (25.8%), alcohol 197 (87.2%), cocaine 115 (43.2%), and THC 108 (40.6%). In 551 (68%) episodes the mechanism was drug intake. Benzodiazepines came first, 423 (76.8%), followed by antidepressants 119 (21.2%) and analgesic/NSAIDs 89 (16.1%). Ingestion of intoxicants was 185 (22.8%), 82 (28.6%) men, 103 (19.7%) women, alcohol in 148 (80%). Self-inflicted injuries were present in 88 (10.9%). There were 331 (40.9%) cases with triggers: relationship problems 115 (34.7%), family problems 106 (32%). 608(75.1%) patients were referred to Mental Health, 73(9%) were admitted to Psychiatric Units.

CONCLUSIONS:

Consulted 810 patients between 2019-2023, an 80.8% increase in ED consultations for suicide attempts during the study period. The majority were women and had a psychiatric history. Approximately half were being followed up in Mental Health. One third had previously attempted suicide. Most were due to medication intake, mainly benzodiazepines. The main triggers were relationship and family problems. 75.1% of patients were referred to Mental Health, 9% were admitted to Psychiatric Units.

01 Oct 2025·ADDICTIVE BEHAVIORS

Article

Author: Efrati, Yaniv

While significant progress has been made in understanding the prevalence of use and severity of addictive behaviors, there remains a lack of research adopting a lay epidemiological approach to examine a broad spectrum of addictive behaviors among a large youth population. The objective of this study is to investigate the frequencies of use and severity of various addictive-like behaviors across different demographic variables including gender, religion, country of birth, religiosity, socio-economic status, and age. The sample comprised 6,849 Jewish and Arabic Israeli youth from the general community, consisting of 2,776 males (41 %) and 4,074 females (59 %), 12-18 years of age (M = 15.92, SD = 1.27) who completed the survey anonymously and with parental consent. Results indicated that higher severity in one addictive behavior correlates with increased severity in others. Substance-related behaviors such as alcohol, tobacco, cannabis, and cocaine showed stronger correlations within their group than with behavioral addictions like gambling, shopping, gaming, eating disorders, sexual activity and social networking. Similarly, behavioral addictions also display stronger correlations within their own cluster. In addition, significant prevalence of use and severity differences were observed in addictive behaviors based on gender, religion, country of birth, religiosity, socio-economic status, and age. The research underscores the critical role of providing support and resources to youth, which is essential for preventing addictive behaviors and reducing the risks associated with their development.

233

News (Medical) associated with Cocaine Hydrochloride

16 Jul 2025

·www.globenewswire.com

Intelligent Bio Solutions Accelerates Global Growth with SmarTest® Patch Agreement, Reinforces U.S. Expansion Path as FDA Approval Remains a Strategic Priority

NEW YORK, July 16, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced a new global distribution agreement with SMARTOX®, a Texas-based leader in drug and alcohol screening services, to bring its SmarTest Patch drug detection product to international markets outside of the United States (“U.S”) and Canada. This partnership builds on the long-standing relationship between INBS and SMARTOX, the U.S. distributor of INBS’s Intelligent Fingerprinting Drug Testing Solution in the Forensic Use Only market. The addition of the SmarTest Patch to INBS’s product portfolio strengthens the Company’s position as a global leader in non-invasive drug testing solutions by introducing continuous sweat-based drug detection over an extended period. The SmarTest Patch opens new opportunities for the Company, particularly in the justice and rehabilitation sectors, at a time when the global drug testing market is projected to grow significantly, reaching approximately $18.6 billion by 20301. The agreement with SMARTOX supports the Company’s international growth strategy and introduces an additional revenue stream aligned with its broader expansion goals. “This partnership with SMARTOX is a natural progression of our relationship and enables us to extend a highly complementary technology to our existing markets,” said Harry Simeonidis, President and CEO at Intelligent Bio Solutions. “With the SmarTest Patch now part of our product portfolio, we can better meet the evolving needs of customers in justice, rehabilitation, and workplace environments.” With this agreement in place, and with two complementary products, INBS can now address short-term and continuous detection needs through sweat-based, non-invasive methods. This positions the Company to offer greater flexibility to customers while continuing to expand its global presence. INBS currently delivers non-invasive drug testing solutions to over 450 active accounts in 24 countries, supporting clients across health, justice, and workplace sectors. As part of its U.S. expansion strategy, INBS continues to prioritize securing FDA clearance for its fingerprint sweat-based drug testing technology for use beyond Forensic Use Only settings. The Company remains actively engaged with regulatory consultants and stakeholders to bring its innovative solution to market in the U.S. for organizations seeking reliable, dignified, and non-invasive drug screening alternatives. About SMARTOX SMARTOX, founded in 2012, is a U.S.-based provider of drug and alcohol testing products and services. It offers a comprehensive portfolio supporting a wide range of settings, including healthcare, justice, corporate, and education. SMARTOX is committed to delivering advanced technology and exceptional results, providing fully integrated services encompassing design, customer service, and administrative support for its product line. The company's footprint spans the U.S. and international markets. SMARTOX is actively scaling its presence in forensic testing markets through new investments, pilot programs, and expanded jurisdictional coverage. About Intelligent Bio Solutions Inc. Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the US include construction, manufacturing and engineering, transport and logistics firms, mining, drug treatment organizations, and coroners. For more information, visit http://www.ibs.inc/ Forward-Looking Statements Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, Intelligent Bio Solutions Inc.’s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure regulatory approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in Intelligent Bio Solutions’ public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of its date. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events. Company ContactIntelligent Bio Solutions Inc.  info@ibs.inc   LinkedIn | Twitter  Investor & Media ContactValter Pinto, Managing Director  KCSA Strategic Communications  PH: (212) 896-1254  INBS@kcsa.com ______________________________ Hyperlinks and website references in this release are provided for convenience only, and do not incorporate the referenced content into this release. 1 Grand View Research (2024). Drug Testing Market Size, Share & Trends Analysis Report By Product (Consumables, Instruments), By Sample (Urine Samples), By Drug (Alcohol, Opioids), By End-use, By Region, And Segment Forecasts, 2025–2030. Available at: https://www.grandviewresearch.com/industry-analysis/drug-testing-market

15 Jul 2025

·www.globenewswire.com

Intelligent Bio Solutions Adds Next-Gen Wearable for Extended Drug Detection to Product Offering, Strengthening Leadership in Non-Invasive Testing

NEW YORK, July 15, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the addition of the SmarTest® Patch to its portfolio of non-invasive drug testing solutions. The SmarTest Patch is an innovative wearable device, developed by SMARTOX®, that enables continuous drug detection through sweat over a 7 to 10-day period. The SmarTest Patch complements the Company's flagship product, the Intelligent Fingerprinting Drug Testing Solution, strengthening its product portfolio of sweat-based, non-invasive testing technologies. The SmarTest Patch is a discreet, water-resistant, and tamper-evident device worn on the skin for 7 to 10 days at a time, continuously collecting sweat to detect a broad range of substances, including cocaine, opiates, methamphetamines, marijuana and fentanyl, among others. The differing detection windows of the SmarTest Patch and the Intelligent Fingerprinting Drug Screening System allows INBS to address varied customer requirements across timeframes, while maintaining a consistent, non-invasive approach. The complementary products increase flexibility and choice for customers, strengthening the Company’s position as a leading provider of pain-free testing solutions. “The SmarTest Patch opens up new opportunities for us in markets where longer detection windows are critical, particularly in justice and rehabilitation settings,” said Doug Heath, Vice President of Global Sales at Intelligent Bio Solutions. “It allows us to offer a more flexible and complete solution to our customers outside the U.S. and strengthens our position as demand continues to grow for non-invasive drug testing options.” The addition of the SmarTest Patch expands the Company's product offering and enhances its commercial edge, equipping customers with more adaptable tools to support short and long-term detection needs. About SMARTOX SMARTOX, founded in 2012, is a U.S.-based provider of drug and alcohol testing products and services. It offers a comprehensive portfolio supporting a wide range of settings, including healthcare, justice, corporate, and education. SMARTOX is committed to delivering advanced technology and exceptional results, providing fully integrated services encompassing design, customer service, and administrative support for its product line. The company's footprint spans the U.S. and international markets. SMARTOX is actively scaling its presence in forensic testing markets through new investments, pilot programs, and expanded jurisdictional coverage. About Intelligent Bio Solutions Inc. Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the US include construction, manufacturing and engineering, transport and logistics firms, mining, drug treatment organizations, and coroners. For more information, visit http://www.ibs.inc/ Forward-Looking Statements Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, Intelligent Bio Solutions Inc.’s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure regulatory approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in Intelligent Bio Solutions’ public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of its date. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events. Company ContactIntelligent Bio Solutions Inc.  info@ibs.inc   LinkedIn | Twitter  Investor & Media ContactValter Pinto, Managing Director  KCSA Strategic Communications  PH: (212) 896-1254  INBS@kcsa.com

10 Jul 2025

·www.globenewswire.com

Intelligent Bio Solutions to Present PK Study Data at Association for Diagnostics and Laboratory Medicine 2025 Clinical Lab Expo

Data shows excretion of codeine in fingerprint sweat INBS’ System is viable option for non-invasive diagnostic testing NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing and screening solutions, today announced that it will present its Pharmacokinetic (“PK”) study data at the Association for Diagnostics and Laboratory Medicine (“ADLM”) 2025 Clinical Lab Expo, taking place July 27–31 in Chicago, Illinois. The PK study collected human fingerprint sweat specimens for laboratory analysis and used INBS’s Intelligent Fingerprinting Drug Screening System (the “System”), a portable, non-invasive system that screens for drugs of abuse via sweat from the fingertips. Study data showed that fingerprint sweat mirrors the rate and extent of codeine found in blood and saliva, making it a strong indicator of codeine ingestion. Statistical comparisons made at the 95% confidence level demonstrated that fingerprint sweat provides a reliable sample matrix for drug detection, with quantitative pharmacokinetic data closely aligning with blood-based results. “ADLM is an important gathering for laboratory medicine professionals, and we’re pleased to share data showing that fingerprint sweat specimens reflect the recent ingestion of codeine. This reinforces that our system of fingerprint sweat testing is a viable option for non-invasive diagnostic testing,” said Daniel Brown, Head of Clinical Affairs at Intelligent Bio Solutions. “We see growing demand for innovative drug screening approaches that are simple to administer, minimize biohazard risks, and offer reliable, rapid results.” Daniel Brown will represent the Company at the event, participating in the ADLM Poster Hall, an open-access forum featuring more than 700 presentations spanning the breadth of laboratory medicine. He will present the background, methodology and findings of the Company’s recent PK Study and will be available during unopposed discussion periods to engage directly with attendees. ADLM 2025 is the world’s premier global laboratory medicine exposition, bringing together international leaders, scientists, and innovators for a week of presentations, workshops, and networking. With over 300 expert speakers, more than 250 educational sessions, and 200 plus product categories, the event offers a platform to explore advances in diagnostic technologies and clinical laboratory innovation. ADLM 2025 is held in partnership with the Canadian Society of Clinical Chemists (CSCC) and covers a broad spectrum of topics, from AI and mass spectrometry to disruptive technologies and diagnostic advancements. Attendees are invited to learn more about INBS’s technology, explore its real-world applications, and connect with the Company’s representatives to discuss collaboration and adoption opportunities. The Company’s Drug Screening System is designed to support accurate, dignified, and efficient testing in workplace, treatment, and justice settings. With more than 450 accounts across 24 countries, INBS continues to expand its reach across numerous sectors, including construction, transportation, engineering, mining, and manufacturing. The Company’s participation in ADLM 2025 highlights its commitment to innovation and growing relevance within laboratory and diagnostic testing communities. About Intelligent Bio Solutions Inc. Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the US include construction, manufacturing and engineering, transport and logistics firms, mining, drug treatment organizations, and coroners. For more information, visit: http://www.ibs.inc Forward-Looking Statements: Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, Intelligent Bio Solutions Inc.'s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure regulatory approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including "believes," "estimates," "anticipates," "expects," "plans," "projects," "intends," "potential," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in Intelligent Bio Solutions' public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of its date. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events. Company Contact:Intelligent Bio Solutions Inc.info@ibs.incLinkedIn | Twitter Investor & Media Contact:Valter Pinto, Managing DirectorKCSA Strategic CommunicationsPH: (212) 896-1254INBS@kcsa

Diagnostic Reagents

100 Deals associated with Cocaine Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D02182	Cocaine Hydrochloride	S01HA01 S02DA02 N01BC01	DB00907

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Anesthesia	United States	Noden Pharma DAC	14 Dec 2017

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Cocaine-Related Disorders	Phase 2	United States	Biotie Therapies Oy	01 Jun 2008

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05809453 (CTgov)	Phase 1/2	Hyperthermia	27	Cocaine+lidocaine (Hot-Humid: Cocaine)	blcwhqwilb(saelrakrjj) = upncwdyycp oiurilspoz (fbdeitctty, 0.32) View more	-	14 Jul 2025
				Lidocaine (Hot-Humid: Lidocaine)	blcwhqwilb(saelrakrjj) = qbbcshmpie oiurilspoz (fbdeitctty, 0.33) View more
ATS2024	Not Applicable	Compartment Syndromes \| Hyperkalemia	-	Cocaine	djmoamdaun(daguwhnqde) = showed a Wellens' pattern with ST-elevation and biphasic T-waves in lead V2-V3 nqjgycpmoy (sfablznbcd ) View more	-	19 May 2024
P2-4.012 (AAN2024)	Not Applicable	Ischemic stroke	-	Cocaine users	mwlbjnvzhr(kqegznljhf) = dnacvyculi sopzpoxdty (nparcgfcwg )	Negative	09 Apr 2024
				Non-cocaine users	mwlbjnvzhr(kqegznljhf) = wytxrtcjkz sopzpoxdty (nparcgfcwg )
SAT439 (ENDO2023)	Not Applicable	Diabetic Ketoacidosis	-	Empagliflozin 25mg daily	amqtgbjwhq(macrzstznd) = Due to patients’ severe acidosis and concerns for cardiac arrest, he was intubated for airway protection and admitted to the ICU for further management. DKA protocol was initiated and treatment with IV insulin, IV 5% Dextrose, 0.45% normal saline, potassium replacement, and IV bicarbonate provided until anion gap closed and acidosis resolved. Eventually, patient was successfully extubated and transferred to ward for further management and diabetic treatment optimization. hbfduuluhw (igtzhvbxiu ) View more	Positive	05 Oct 2023
ATS2023	Not Applicable	Complication	-	Cocaine inhalation	gmeepoyxzx(hkuvlqsmkx) = Prevention of pulmonary toxicity requires cessation of cocaine use and a referral to a substance use treatment program is advised. oiacqtdghc (yxxzfbndng ) View more	-	21 May 2023
ATS2023	Not Applicable	Bronchiolitis	-	Cocaine	lycdrdwtxw(axkfsjhrsz) = plwgienfyj wnvmivokxy (oibdklpnvj ) View more	-	21 May 2023
NCT02537873 (CTgov)	Phase 1	Cocaine-Related Disorders	29	Cocaine+Lorcaserin (Arm 1: Lorcaserin and Cocaine IV)	vrnjascveq(ldywwspztk) = htnxrvycuj hsvlztnfcw (ahejhwqcpr, 7.98) View more	-	12 May 2020
				Cocaine+Placebo comparator (Arm 2: Placebo Comparator and Cocaine IV)	vrnjascveq(ldywwspztk) = hgybpzdclt hsvlztnfcw (ahejhwqcpr, 6.94) View more
NCT01906346 (CTgov)	Early Phase 1	Cocaine-Related Disorders	9	Placebo+Cocaine (Low Value Alternative Reinforcer)	qwmdhkxpzh(dfsuldupwv) = jwdszqzkxo vtkrijoqty (oauwsthupy, 1.39) View more	-	17 May 2019
				Placebo+Cocaine (Medium Value Reinforcer)	qwmdhkxpzh(dfsuldupwv) = oegjutpsby vtkrijoqty (oauwsthupy, 0.53) View more
NCT02383043 (CTgov)	Early Phase 1	Cocaine-Related Disorders	18	Cocaine+Sustained Release d-Amphetamine	yliynoipdq(ffuvkutiph) = etghfhamaa xggzlwzybc (pkmkwpglrj, 0.35) View more	-	11 Apr 2019
AAN2018	Not Applicable	Acute Ischemic Stroke cocaine use	-	AIS with cocaine use	tbznvbmlsa(iprizxalud) = hxmtjdotcd fasbijjdfa (qtodpllxdu ) View more	-	10 Apr 2018
				AIS without cocaine use	tbznvbmlsa(iprizxalud) = emdrhjhwuh fasbijjdfa (qtodpllxdu ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis